Supplementary Material for:

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

Kasper Lamberth,* Stine Louise Reedtz-Runge, Jonathan Simon, Ksenia Klementyeva, Gouri Shankar Pandey, Søren Berg Padkjær, Véronique Pascal, Ileana R. León, Charlotte Nini Gudme, Søren Buus, Zuben E. Sauna*

*Corresponding author. Email: zuben.sauna{at}fda.hhs.gov (Z.E.S.); kplm{at}novonordisk.com (K.L.)

Published 11 January 2017, Sci. Transl. Med. 9, eaag1286 (2017)
DOI: 10.1126/scitranslmed.aag1286

This PDF file includes:

• Materials and Methods
• Table S1. Synthetic peptides used in the ELISpot assays shown in Fig. 3.
• Table S2. Synthetic peptides used in the ELISpot and proliferation assays depicted in Fig. 4.
• Table S3. List of MHC-II DRB1 variants depicted in Fig. 5D.
• Fig. S1. Heat maps similar to the one depicted in Fig. 1D plotted on different scales for peptide–MHC-II affinity.
• Reference (29)

[Download PDF]